

Tremfya (guselkumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:		FIRST NAME:
PHONE NUMBER:		DATE OF BIRTH:
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

☐ MALE ☐ FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](https://www.primetherapeutics.com/nopp)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

Tremfya (guselkumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?

☐ YES (if yes, complete below) ☐ NO

MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:

2. LIST DIAGNOSES:

ICD-10:

- ☐ Plaque psoriasis
☐ Psoriatic arthritis
☐ Ulcerative colitis
☐ Crohn's disease
☐ Other diagnosis: _____ ICD-10 Code(s): _____

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Is patient going to be using drug in combination with a clinical trial? ☐ Yes ☐ No

Initial Request:

Will the patient be using Tremfya concurrently with another biologic response modifier or immunomodulatory agent? ☐ Yes ☐ No

Will patient stop use of their biologic response modifier or immunomodulatory agent when they start use with Tremfya? ☐ Yes ☐ No

Select if the patient has had at least a 3-month trial and inadequate response to the Humira biosimilar adalimumab-aacf? ☐ Yes ☐ No Please submit documentation.

Does patient have an absolute contraindication to the biosimilar adalimumab-aacf? ☐ Yes ☐ No Please submit documentation.

Is Tremfya prescribed by a dermatologist? ☐ Yes ☐ No

Is Tremfya prescribed by a rheumatologist? ☐ Yes ☐ No

Is Tremfya prescribed by a gastroenterologist? ☐ Yes ☐ No

For Plaque Psoriasis / Psoriatic Arthritis:

Does the patient have plaques covering at least 10% of their body surface area (BSA) or less than 10% of BSA with involvement of palms, soles, head and neck, or genitalia which cause disruption of normal activities? ☐ Yes ☐ No

Has the patient had an inadequate response to topical therapy (e.g., corticosteroids, anthralin, calcipotriene, tazarotene)?* ☐ Yes ☐ No

Select if the patient has had a trial and inadequate response to the following phototherapy options:

☐ Psoralens with UVA light (PUVA)

Tremfya (guselkumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

☐ UVB with coal tar

Has patient had a trial and failure with a three-month course of one of the following conventional disease modifying anti-rheumatic agents (DMARDs) [e.g., methotrexate, acitretin, sulfasalazine [Azulfidine®], leflunamide [Arava®] or hydroxychloroquine or cyclosporine)?

☐ Yes ☐ No Please submit documentation.

Does the patient have documentation of a contraindication to all conventional DMARD systemic therapies indicated for their disease? ☐ Yes ☐ No **Must provide documentation*

For Ulcerative colitis:

Has patient tried and failed at least one of the following three therapies: corticosteroids, azathioprine and/or 6-mercaptopurine? ☐ Yes ☐ No Please provide documentation.

For Crohn's Disease:

Has patient had a trial of glucocorticoid therapy or methotrexate or azathioprine or 6-mercaptopurine or 5-ASA/mesalamine? ☐ Yes ☐ No Please submit documentation.

Renewal Request:

Is prescriber a dermatologist? ☐ Yes ☐ No

Is prescriber a rheumatologist? ☐ Yes ☐ No

Is Tremfya prescribed by a gastroenterologist? ☐ Yes ☐ No

Is patient continuing to respond to therapy? ☐ Yes ☐ No Please submit documentation.

Will patient use requested medication in combination with another biologic response modifier or immunomodulatory agent? ☐ Yes ☐ No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

Tremfya (guselkumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909